The multifaceted mechanisms of malignant glioblastoma progression and clinical implications

1.

Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., Group, N. C. I. o. C. C. T. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine, 352(10), 987–996. https://doi.org/10.1056/NEJMoa043330CrossRef

2.

Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Group, N. C. I. o. C. C. T. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The lancet Oncology, 10(5), 459–466. https://doi.org/10.1016/S1470-2045(09)70025-7CrossRef

3.

Li, X., Shao, C., Shi, Y., & Han, W. (2018). Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. Journal of Hematology & Oncology, 11(1), 31. https://doi.org/10.1186/s13045-018-0578-4CrossRef

4.

Sanmamed, M. F., & Chen, L. (2018). A paradigm shift in cancer immunotherapy: From enhancement to normalization. Cell, 175(2), 313–326. https://doi.org/10.1016/j.cell.2018.09.035CrossRef

5.

Sondak, V. K., Smalley, K. S., Kudchadkar, R., Grippon, S., & Kirkpatrick, P. (2011). Ipilimumab. Nature Reviews. Drug Discovery, 10(6), 411–412. https://doi.org/10.1038/nrd3463CrossRef

6.

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J., Robert, L., & Ribas, A. (2014). PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature, 515(7528), 568571. https://doi.org/10.1038/nature13954CrossRef

7.

Akintola, O. O., & Reardon, D. A. (2021). The current landscape of immune checkpoint blockade in glioblastoma. Neurosurgery Clinics of North America, 32(2), 235–248. https://doi.org/10.1016/j.nec.2020.12.003CrossRef

8.

Yang, T., Kong, Z., & Ma, W. (2021). PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: Clinical studies, challenges and potential. Human Vaccines & Immunotherapeutics, 17(2), 546–553. https://doi.org/10.1080/21645515.2020.1782692CrossRef

9.

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013CrossRef

10.

de Gooijer, M. C., Guillén Navarro, M., Bernards, R., Wurdinger, T., & van Tellingen, O. (2018). An experimenter’s guide to glioblastoma invasion pathways. Trends in Molecular Medicine, 24(9), 763–780. https://doi.org/10.1016/j.molmed.2018.07.003CrossRef

11.

Wen, P. Y., & Kesari, S. (2008). Malignant gliomas in adults. Erratum IN: N Engl J Med., 359(5), 492–507. https://doi.org/10.1056/NEJMra0708126CrossRef

12.

Cuddapah, V. A., Robel, S., Watkins, S., & Sontheimer, H. (2014). A neurocentric perspective on glioma invasion. Nature Reviews Neuroscience, 15(7), 455–465. https://doi.org/10.1038/nrn3765CrossRef

13.

Gritsenko, P. G., Ilina, O., & Friedl, P. (2012). Interstitial guidance of cancer invasion. The Journal of Pathology, 226(2), 185–199. https://doi.org/10.1002/path.3031CrossRef

14.

Novak, U., & Kaye, A. H. (2000). Extracellular matrix and the brain: Components and function. Journal of Clinical Neuroscience, 7(4), 280–290. https://doi.org/10.1054/jocn.1999.0212CrossRef

15.

Thomsen, M. S., Routhe, L. J., & Moos, T. (2017). The vascular basement membrane in the healthy and pathological brain. Journal of Cerebral Blood Flow and Metabolism, 37(10), 3300–3317. https://doi.org/10.1177/0271678X17722436CrossRef

16.

Persidsky, Y., Ramirez, S. H., Haorah, J., & Kanmogne, G. D. (2006). Blood-brain barrier: Structural components and function under physiologic and pathologic conditions. Journal of Neuroimmune Pharmacology, 1(3), 223–236. https://doi.org/10.1007/s11481-006-9025-3CrossRef

17.

Kalluri, R. (2003). Basement membranes: Structure, assembly and role in tumour angiogenesis. Nature Reviews Cancer, 3(6), 422–433. https://doi.org/10.1038/nrc1094CrossRef

18.

Barnes, J. M., Kaushik, S., Bainer, R. O., Sa, J. K., Woods, E. C., Kai, F., & Weaver, V. M. (2018). A tension-mediated glycocalyx-integrin feedback loop promotes mesenchymal-like glioblastoma. Nature Cell Biology, 20(10), 1203–1214. https://doi.org/10.1038/s41556-018-0183-3CrossRef

19.

Paszek, M. J., DuFort, C. C., Rossier, O., Bainer, R., Mouw, J. K., Godula, K., & Weaver, V. M. (2014). The cancer glycocalyx mechanically primes integrin-mediated growth and survival. Nature, 511(7509), 319–325. https://doi.org/10.1038/nature13535CrossRef

20.

Miroshnikova, Y. A., Mouw, J. K., Barnes, J. M., Pickup, M. W., Lakins, J. N., Kim, Y., & Weaver, V. M. (2016). Tissue mechanics promote IDH1-dependent HIF1α-tenascin C feedback to regulate glioblastoma aggression. Nature Cell Biology, 18(12), 1336–1345. https://doi.org/10.1038/ncb3429CrossRef

21.

Tran, V. M., Wade, A., McKinney, A., Chen, K., Lindberg, O. R., Engler, J. R., & Phillips, J. J. (2017). Heparan sulfate glycosaminoglycans in glioblastoma promote tumor invasion. Molecular Cancer Research, 15(11), 1623–1633. https://doi.org/10.1158/1541-7786.MCR-17-0352CrossRef

22.

Logun, M. T., Wynens, K. E., Simchick, G., Zhao, W., Mao, L., Zhao, Q., & Karumbaiah, L. (2019). Surfen-mediated blockade of extratumoral chondroitin sulfate glycosaminoglycans inhibits glioblastoma invasion. The FASEB Journal, 33(11), 11973–11992. https://doi.org/10.1096/fj.201802610RRCrossRef

23.

Ferrer, V. P., Moura Neto, V., & Mentlein, R. (2018). Glioma infiltration and extracellular matrix: Key players and modulators. Glia, 66(8), 1542–1565. https://doi.org/10.1002/glia.23309CrossRef

24.

Wade, A., Robinson, A. E., Engler, J. R., Petritsch, C., James, C. D., & Phillips, J. J. (2013). Proteoglycans and their roles in brain cancer. FEBS Journal, 280(10), 2399–2417. https://doi.org/10.1111/febs.12109CrossRef

25.

Miyata, S., & Kitagawa, H. (2016). Chondroitin 6-sulfation regulates perineuronal net formation by controlling the stability of aggrecan. Neural Plasticity, 2016, 1305801. https://doi.org/10.1155/2016/1305801CrossRef

26.

Belousov, A., Titov, S., Shved, N., Garbuz, M., Malykin, G., Gulaia, V., & Kumeiko, V. (2019). The extracellular matrix and biocompatible materials in glioblastoma treatment. Front Bioeng Biotechnol, 7, 341. https://doi.org/10.3389/fbioe.2019.00341CrossRef

27.

Lu, R., Wu, C., Guo, L., Liu, Y., Mo, W., Wang, H., & Yu, M. (2012). The role of brevican in glioma: Promoting tumor cell motility in vitro and in vivo. BMC Cancer, 12, 607. https://doi.org/10.1186/1471-2407-12-607CrossRef

28.

Dwyer, C. A., Bi, W. L., Viapiano, M. S., & Matthews, R. T. (2014). Brevican knockdown reduces late-stage glioma tumor aggressiveness. Journal of Neuro-oncology, 120(1), 63–72. https://doi.org/10.1007/s11060-014-1541-zCrossRef

29.

Onken, J., Moeckel, S., Leukel, P., Leidgens, V., Baumann, F., Bogdahn, U., & Hau, P. (2014). Versican isoform V1 regulates proliferation and migration in high-grade gliomas. Journal of Neuro-oncology, 120(1), 73–83. https://doi.org/10.1007/s11060-014-1545-8CrossRef

30.

Hu, F., Dzaye, O., Hahn, A., Yu, Y., Scavetta, R. J., Dittmar, G., & Kettenmann, H. (2015). Glioma-derived versican promotes tumor expansion via glioma-associated microglial/macrophages Toll-like receptor 2 signaling. Neuro-Oncology, 17(2), 200–210. https://doi.org/10.1093/neuonc/nou324CrossRef

31.

Chen, J. E., Pedron, S., Shyu, P., Hu, Y., Sarkaria, J. N., & Harley, B. A. C. (2018). Influence of hyaluronic acid transitions in tumor microenvironment on glioblastoma malignancy and invasive behavior. Front Mater, 5 https://doi.org/10.3389/fmats.2018.00039

32.

Yoo, K. C., Suh, Y., An, Y., Lee, H. J., Jeong, Y. J., Uddin, N., & Lee, S. J. (2018). Proinvasive extracellular matrix remodeling in tumor microenvironment in response to radiation. Oncogene, 37(24), 3317–3328. https://doi.org/10.1038/s41388-018-0199-yCrossRef

33.

Friedl, P., & Wolf, K. (2003). Tumour-cell invasion and migration: Diversity and escape mechanisms. Nature Reviews Cancer, 3(5), 362–374. https://doi.org/10.1038/nrc1075CrossRef

34.

Sanz-Moreno, V., Gadea, G., Ahn, J., Paterson, H., Marra, P., Pinner, S., & Marshall, C. J. (2008). Rac activation and inactivation control plasticity of tumor cell movement. Cell, 135(3), 510–523. https://doi.org/10.1016/j.cell.2008.09.043CrossRef

35.

Beadle, C., Assanah, M. C., Monzo, P., Vallee, R., Rosenfeld, S. S., & Canoll, P. (2008). The role of myosin II in glioma invasion of the brain. Molecular Biology of the Cell, 19(8), 3357–3368. https://doi.org/10.1091/mbc.e08-03-0319CrossRef

36.

Caspani, E. M., Echevarria, D., Rottner, K., & Small, J. V. (2006). Live imaging of glioblastoma cells in brain tissue shows requirement of actin bundles for migration. Neuron Glia Biology, 2(2), 105–114. https://doi.org/10.1017/S1740925X06000111CrossRef

37.

Cui, Y., Cole, S., Pepper, J., Otero, J. J., & Winter, J. O. (2020). Hyaluronic acid induces ROCK-dependent amoeboid migration in glioblastoma cells. Biomater Sci, 8(17), 4821–4831. https://doi.org/10.1039/d0bm00505cCrossRef

38.

Zhai, G. G., Malhotra, R., Delaney, M., Latham, D., Nestler, U., Zhang, M., & Chakravarti, A. (2006). Radiation enhances the invasive potential of primary glioblastoma cells via activation of the Rho signaling pathway. Journal of Neuro-oncology, 76(3), 227–237. https://doi.org/10.1007/s11060-005-6499-4CrossRef

39.

Domogatskaya, A., Rodin, S., & Tryggvason, K. (2012). Functional diversity of laminins. Annual Review of Cell and Developmental Biology, 28, 523–553. https://doi.org/10.1146/annurev-cellbio-101011-155750CrossRef

40.

Yap, L., Tay, H. G., Nguyen, M. T. X., Tjin, M. S., & Tryggvason, K. (2019). Laminins in cellular differentiation. Trends in Cell Biology, 29(12), 987–1000. https://doi.org/10.1016/j.tcb.2019.10.001CrossRef

41.

Ljubimova, J. Y., Lakhter, A. J., Loksh, A., Yong, W. H., Riedinger, M. S., Miner, J. H., & Black, K. L. (2001). Overexpression of alpha4 chain-containing laminins in human glial tumors identified by gene microarray analysis. Cancer Research, 61(14), 5601–5610.

42.

Ljubimova, J. Y., Fugita, M., Khazenzon, N. M., Das, A., Pikul, B. B., Newman, D., & Black, K. L. (2004). Association between laminin-8 and glial tumor grade, recurrence, and patient survival. Cancer, 101(3), 604–612. https://doi.org/10.1002/cncr.20397CrossRef

43.

Sun, T., Patil, R., Galstyan, A., Klymyshyn, D., Ding, H., Chesnokova, A., & Ljubimova, J. Y. (2019). Blockade of a laminin-411-notch axis with CRISPR/Cas9 or a nanobioconjugate inhibits glioblastoma growth through tumor-microenvironment cross-talk. Cancer Research, 79(6), 1239–1251. https://doi.org/10.1158/0008-5472.CAN-18-2725CrossRef

44.

Rascher, G., Fischmann, A., Kröger, S., Duffner, F., Grote, E. H., & Wolburg, H. (2002). Extracellular matrix and the blood-brain barrier in glioblastoma multiforme: Spatial segregation of tenascin and agrin. Acta Neuropathologica, 104(1), 85–91. https://doi.org/10.1007/s00401-002-0524-xCrossRef

45.

Zagzag, D., Friedlander, D. R., Miller, D. C., Dosik, J., Cangiarella, J., Kostianovsky, M., & Greco, M. A. (1995). Tenascin expression in astrocytomas correlates with angiogenesis. Cancer Research, 55(4), 907–914.

46.

Rupp, T., Langlois, B., Koczorowska, M. M., Radwanska, A., Sun, Z., Hussenet, T., & Orend, G. (2016). Tenascin-C orchestrates glioblastoma angiogenesis by modulation of pro- and anti-angiogenic signaling. Cell Reports, 17(10), 2607–2619. https://doi.org/10.1016/j.celrep.2016.11.012CrossRef

47.

Lal, A., Lash, A. E., Altschul, S. F., Velculescu, V., Zhang, L., McLendon, R. E., & Riggins, G. J. (1999). A public database for gene expression in human cancers. Cancer Research, 59(21), 5403–5407.

48.

Serres, E., Debarbieux, F., Stanchi, F., Maggiorella, L., Grall, D., Turchi, L., & Van Obberghen-Schilling, E. (2014). Fibronectin expression in glioblastomas promotes cell cohesion, collective invasion of basement membrane in vitro and orthotopic tumor growth in mice. Oncogene, 33(26), 3451–3462. https://doi.org/10.1038/onc.2013.305CrossRef

49.

Hynes, R. O. (2009). The extracellular matrix: Not just pretty fibrils. Science, 326(5957), 1216–1219. https://doi.org/10.1126/science.1176009CrossRef

50.

Cseh, B., Fernandez-Sauze, S., Grall, D., Schaub, S., Doma, E., & Van Obberghen-Schilling, E. (2010). Autocrine fibronectin directs matrix assembly and crosstalk between cell-matrix and cell-cell adhesion in vascular endothelial cells. Journal of Cell Science, 123(Pt 22), 3989–3999. https://doi.org/10.1242/jcs.073346CrossRef

51.

Blandin, A. F., Noulet, F., Renner, G., Mercier, M. C., Choulier, L., Vauchelles, R., & Lehmann, M. (2016). Glioma cell dispersion is driven by α5 integrin-mediated cell-matrix and cell-cell interactions. Cancer Letters, 376(2), 328–338. https://doi.org/10.1016/j.canlet.2016.04.007CrossRef

52.

Pencheva, N., de Gooijer, M. C., Vis, D. J., Wessels, L. F. A., Würdinger, T., van Tellingen, O., & Bernards, R. (2017). Identification of a druggable pathway controlling glioblastoma invasiveness. Cell Reports, 20(1), 48–60. https://doi.org/10.1016/j.celrep.2017.06.036CrossRef

53.

Pointer, K. B., Clark, P. A., Schroeder, A. B., Salamat, M. S., Eliceiri, K. W., & Kuo, J. S. (2017). Association of collagen architecture with glioblastoma patient survival. Journal of Neurosurgery, 126(6), 1812–1821. https://doi.org/10.3171/2016.6.JNS152797CrossRef

54.

Codega, P., & Mellinghoff, I. K. (2017). Dissecting glioma invasiveness in a 3D-organotypic model. Trends in Molecular Medicine, 23(9), 776–777. https://doi.org/10.1016/j.molmed.2017.07.009CrossRef

55.

Wolf, K. J., Chen, J., Coombes, J., Aghi, M. K., & Kumar, S. (2019). Dissecting and rebuilding the glioblastoma microenvironment with engineered materials. Nature Reviews Materials, 4(10), 651–668. https://doi.org/10.1038/s41578-019-0135-yCrossRef

56.

Hatoum, A., Mohammed, R., & Zakieh, O. (2019). The unique invasiveness of glioblastoma and possible drug targets on extracellular matrix. Cancer Manag Res, 11, 1843–1855. https://doi.org/10.2147/CMAR.S186142CrossRef

57.

Rajesh, Y., Biswas, A., Kumar, U., Das, S., Banerjee, I., Banik, P., & Mandal, M. (2019). Targeting NFE2L2, a transcription factor upstream of MMP-2: A potential therapeutic strategy for temozolomide resistant glioblastoma. Biochemical Pharmacology, 164, 1–16. https://doi.org/10.1016/j.bcp.2019.03.025CrossRef

58.

Huleihel, L., Hussey, G. S., Naranjo, J. D., Zhang, L., Dziki, J. L., Turner, N. J., & Badylak, S. F. (2016). Matrix-bound nanovesicles within ECM bioscaffolds. Science Advances, 2(6), e1600502. https://doi.org/10.1126/sciadv.1600502CrossRef

59.

Yekula, A., Muralidharan, K., Kang, K., Carter, B. S., & Balaj, L. (2019). Extracellular vesicles in glioblastoma tumor microenvironment. Frontiers in Immunology, 10, 3137. https://doi.org/10.3389/fimmu.2019.03137CrossRef

60.

Han, L., Lam, E. W., & Sun, Y. (2019). Extracellular vesicles in the tumor microenvironment: Old stories, but new tales. Molecular Cancer, 18(1), 59. https://doi.org/10.1186/s12943-019-0980-8CrossRef

61.

Simon, T., Jackson, E., & Giamas, G. (2020). Breaking through the glioblastoma micro-environment via extracellular vesicles. Oncogene, 39(23), 4477–4490. https://doi.org/10.1038/s41388-020-1308-2CrossRef

62.

Redzic, J. S., Ung, T. H., & Graner, M. W. (2014). Glioblastoma extracellular vesicles: Reservoirs of potential biomarkers. Pharmgenomics Pers Med, 7, 65–77. https://doi.org/10.2147/PGPM.S39768CrossRef

63.

Humphrey, J. D., Dufresne, E. R., & Schwartz, M. A. (2014). Mechanotransduction and extracellular matrix homeostasis. Nature Reviews Molecular Cell Biology, 15(12), 802–812. https://doi.org/10.1038/nrm3896CrossRef

64.

Wells, R. G. (2008). The role of matrix stiffness in regulating cell behavior. Hepatology, 47(4), 1394–1400. https://doi.org/10.1002/hep.22193CrossRef

65.

Seewaldt, V. (2014). ECM stiffness paves the way for tumor cells. Nature Medicine, 20(4), 332–333. https://doi.org/10.1038/nm.3523CrossRef

66.

Najafi, M., Farhood, B., & Mortezaee, K. (2019). Extracellular matrix (ECM) stiffness and degradation as cancer drivers. Journal of Cellular Biochemistry, 120(3), 2782–2790. https://doi.org/10.1002/jcb.27681CrossRef

67.

Discher, D. E., Janmey, P., & Wang, Y. L. (2005). Tissue cells feel and respond to the stiffness of their substrate. Science, 310(5751), 1139–1143. https://doi.org/10.1126/science.1116995CrossRef

68.

Broders-Bondon, F., Nguyen Ho-Bouldoires, T. H., Fernandez-Sanchez, M. E., & Farge, E. (2018). Mechanotransduction in tumor progression: The dark side of the force. Journal of Cell Biology, 217(5), 1571–1587. https://doi.org/10.1083/jcb.201701039CrossRef

69.

Mohan, V., Das, A., & Sagi, I. (2020). Emerging roles of ECM remodeling processes in cancer. Seminars in Cancer Biology, 62, 192–200. https://doi.org/10.1016/j.semcancer.2019.09.004CrossRef

70.

Yamashiro, Y., Thang, B. Q., Ramirez, K., Shin, S. J., Kohata, T., Ohata, S., & Yanagisawa, H. (2020). Matrix mechanotransduction mediated by thrombospondin-1/integrin/YAP in the vascular remodeling. Proc Natl Acad Sci U S A, 117(18), 9896–9905. https://doi.org/10.1073/pnas.1919702117CrossRef

71.

Wolf, K. J., & Kumar, S. (2019). Hyaluronic acid: Incorporating the bio into the material. ACS Biomaterials Science & Engineering, 5(8), 3753–3765. https://doi.org/10.1021/acsbiomaterials.8b01268CrossRef

72.

Mohammadi, H., & Sahai, E. (2018). Mechanisms and impact of altered tumour mechanics. Nature Cell Biology, 20(7), 766–774. https://doi.org/10.1038/s41556-018-0131-2CrossRef

73.

Ulrich, T. A., de Juan Pardo, E. M., & Kumar, S. (2009). The mechanical rigidity of the extracellular matrix regulates the structure, motility, and proliferation of glioma cells. Cancer Research, 69(10), 4167–4174. https://doi.org/10.1158/0008-5472.CAN-08-4859CrossRef

74.

Wang, C., Tong, X., & Yang, F. (2014). Bioengineered 3D brain tumor model to elucidate the effects of matrix stiffness on glioblastoma cell behavior using PEG-based hydrogels. Molecular Pharmaceutics, 11(7), 2115–2125. https://doi.org/10.1021/mp5000828CrossRef

75.

Wang, C., Sinha, S., Jiang, X., Murphy, L., Fitch, S., Wilson, C., & Yang, F. (2021). Matrix stiffness modulates patient-derived glioblastoma cell fates in three-dimensional hydrogels. Tissue Engineering Part A, 27(5–6), 390–401. https://doi.org/10.1089/ten.TEA.2020.0110CrossRef

76.

Fattet, L., Jung, H. Y., Matsumoto, M. W., Aubol, B. E., Kumar, A., Adams, J. A., & Yang, J. (2020). Matrix rigidity controls epithelial-mesenchymal plasticity and tumor metastasis via a mechanoresponsive EPHA2/LYN complex. Developmental Cell, 54(3), 302-316.e307. https://doi.org/10.1016/j.devcel.2020.05.031CrossRef

77.

Sun, M., Spill, F., & Zaman, M. H. (2016). A computational model of YAP/TAZ mechanosensing. Biophysical Journal, 110(11), 2540–2550. https://doi.org/10.1016/j.bpj.2016.04.040CrossRef

78.

Zanconato, F., Cordenonsi, M., & Piccolo, S. (2019). YAP and TAZ: A signalling hub of the tumour microenvironment. Nature Reviews Cancer, 19(8), 454–464. https://doi.org/10.1038/s41568-019-0168-yCrossRef

79.

Cooper, J., & Giancotti, F. G. (2019). Integrin signaling in cancer: Mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance. Cancer Cell, 35(3), 347–367. https://doi.org/10.1016/j.ccell.2019.01.007CrossRef

80.

Park, J. S., Burckhardt, C. J., Lazcano, R., Solis, L. M., Isogai, T., Li, L., & Danuser, G. (2020). Mechanical regulation of glycolysis via cytoskeleton architecture. Nature, 578(7796), 621–626. https://doi.org/10.1038/s41586-020-1998-1CrossRef

81.

Fernie, A. R., Zhang, Y., & Sampathkumar, A. (2020). Cytoskeleton architecture regulates glycolysis coupling cellular metabolism to mechanical cues. Trends in Biochemical Sciences, 45(8), 637–638. https://doi.org/10.1016/j.tibs.2020.04.003CrossRef

82.

Bertero, T., Oldham, W. M., Grasset, E. M., Bourget, I., Boulter, E., Pisano, S., & Gaggioli, C. (2019). Tumor-stroma mechanics coordinate amino acid availability to sustain tumor growth and malignancy. Cell Metabolism, 29(1), 124-140.e110. https://doi.org/10.1016/j.cmet.2018.09.012CrossRef

83.

Khoonkari, M., Liang, D., Kamperman, M., Kruyt, F. A. E., & van Rijn, P. (2022). Physics of brain cancer: Multiscale alterations of glioblastoma cells under extracellular matrix stiffening. Pharmaceutics, 14(5). https://doi.org/10.3390/pharmaceutics14051031

84.

Zhang, J., & Reinhart-King, C. A. (2020). Targeting tissue stiffness in metastasis: Mechanomedicine improves cancer therapy. Cancer Cell, 37(6), 754–755. https://doi.org/10.1016/j.ccell.2020.05.011CrossRef

85.

Shen, Y., Wang, X., Lu, J., Salfenmoser, M., Wirsik, N. M., Schleussner, N., & Schmidt, T. (2020). Reduction of liver metastasis stiffness improves response to bevacizumab in metastatic colorectal cancer. Cancer Cell, 37(6), 800-817.e807. https://doi.org/10.1016/j.ccell.2020.05.005CrossRef

86.

Friebel, E., Kapolou, K., Unger, S., Núñez, N. G., Utz, S., Rushing, E. J., & Becher, B. (2020). Single-cell mapping of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes. Cell, 181(7), 1626-1642.e1620. https://doi.org/10.1016/j.cell.2020.04.055CrossRef

87.

Tomaszewski, W., Sanchez-Perez, L., Gajewski, T. F., & Sampson, J. H. (2019). Brain tumor microenvironment and host state: Implications for immunotherapy. Clinical Cancer Research, 25(14), 4202–4210. https://doi.org/10.1158/1078-0432.CCR-18-1627CrossRef

88.

Bayik, D., Zhou, Y., Park, C., Hong, C., Vail, D., Silver, D. J., & Lathia, J. D. (2020). Myeloid-derived suppressor cell subsets drive glioblastoma growth in a sex-specific manner. Cancer Discovery, 10(8), 1210–1225. https://doi.org/10.1158/2159-8290.CD-19-1355CrossRef

89.

Gutmann, D. H., & Kettenmann, H. (2019). Microglia/brain macrophages as central drivers of brain tumor pathobiology. Neuron, 104(3), 442–449. https://doi.org/10.1016/j.neuron.2019.08.028CrossRef

90.

Chen, Z., Feng, X., Herting, C. J., Garcia, V. A., Nie, K., Pong, W. W., & Hambardzumyan, D. (2017). Cellular and molecular identity of tumor-associated macrophages in glioblastoma. Cancer Research, 77(9), 2266–2278. https://doi.org/10.1158/0008-5472.CAN-16-2310CrossRef

91.

Klemm, F., Maas, R. R., Bowman, R. L., Kornete, M., Soukup, K., Nassiri, S., & Joyce, J. A. (2020). Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells. Cell, 181(7), 1643-1660.e1617. https://doi.org/10.1016/j.cell.2020.05.007CrossRef

92.

Colonna, M., & Butovsky, O. (2017). Microglia function in the central nervous system during health and neurodegeneration. Annual Review of Immunology, 35, 441–468. https://doi.org/10.1146/annurev-immunol-051116-052358CrossRef

93.

Hickman, S. E., Kingery, N. D., Ohsumi, T. K., Borowsky, M. L., Wang, L. C., Means, T. K., & El Khoury, J. (2013). The microglial sensome revealed by direct RNA sequencing. Nature Neuroscience, 16(12), 1896–1905. https://doi.org/10.1038/nn.3554CrossRef

94.

Sørensen, M. D., Dahlrot, R. H., Boldt, H. B., Hansen, S., & Kristensen, B. W. (2018). Tumour-associated microglia/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumour subtype. Neuropathology and Applied Neurobiology, 44(2), 185–206. https://doi.org/10.1111/nan.12428CrossRef

95.

Kloosterman, D. J., & Akkari, L. (2020). Mapping the uncharted territories of human brain malignancies. Cell, 181(7), 1454–1457. https://doi.org/10.1016/j.cell.2020.06.003CrossRef

96.

Hambardzumyan, D., Gutmann, D. H., & Kettenmann, H. (2016). The role of microglia and macrophages in glioma maintenance and progression. Nature Neuroscience, 19(1), 20–27. https://doi.org/10.1038/nn.4185CrossRef

97.

Darmanis, S., Sloan, S. A., Croote, D., Mignardi, M., Chernikova, S., Samghababi, P., & Quake, S. R. (2017). Single-cell RNA-Seq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma. Cell Reports, 21(5), 1399–1410. https://doi.org/10.1016/j.celrep.2017.10.030CrossRef

98.

Landry, A. P., Balas, M., Alli, S., Spears, J., & Zador, Z. (2020). Distinct regional ontogeny and activation of tumor associated macrophages in human glioblastoma. Science and Reports, 10(1), 19542. https://doi.org/10.1038/s41598-020-76657-3CrossRef

99.

Chen, P., Zhao, D., Li, J., Liang, X., Chang, A., Henry, V. K., & DePinho, R. A. (2019). Symbiotic macrophage-glioma cell interactions reveal synthetic lethality in PTEN-null glioma. Cancer Cell, 35(6), 868-884.e866. https://doi.org/10.1016/j.ccell.2019.05.003CrossRef

100.

Hara, T., Chanoch-Myers, R., Mathewson, N. D., Myskiw, C., Atta, L., Bussema, L., & Tirosh, I. (2021). Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. Cancer Cell, 39(6), 779-792.e711. https://doi.org/10.1016/j.ccell.2021.05.002CrossRef

101.

Song, K., Yuan, Y., Lin, Y., Wang, Y. X., Zhou, J., Gai, Q. J., & Wang, Y. (2018). ERBB3, IGF1R, and TGFBR2 expression correlate with PDGFR expression in glioblastoma and participate in PDGFR inhibitor resistance of glioblastoma cells. American Journal of Cancer Research, 8(5), 792–809.

102.

Wallmann, T., Zhang, X. M., Wallerius, M., Bolin, S., Joly, A. L., Sobocki, C., Rolny, C. (2018). Microglia induce PDGFRB expression in glioma cells to enhance their migratory capacity. iScience, 9, 71–83. https://doi.org/10.1016/j.isci.2018.10.011

103.

Vinnakota, K., Hu, F., Ku, M. C., Georgieva, P. B., Szulzewsky, F., Pohlmann, A., & Kettenmann, H. (2013). Toll-like receptor 2 mediates microglia/brain macrophage MT1-MMP expression and glioma expansion. Neuro-Oncology, 15(11), 1457–1468. https://doi.org/10.1093/neuonc/not115CrossRef

104.

Hu, F., Ku, M. C., Markovic, D., Dzaye, O., Lehnardt, S., Synowitz, M., & Kettenmann, H. (2014). Glioma-associated microglial MMP9 expression is upregulated by TLR2 signaling and sensitive to minocycline. International Journal of Cancer, 135(11), 2569–2578. https://doi.org/10.1002/ijc.28908CrossRef

105.

Dumas, A. A., Pomella, N., Rosser, G., Guglielmi, L., Vinel, C., Millner, T. O., & Marino, S. (2020). Microglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment. EMBO Journal, 39(15), e103790. https://doi.org/10.15252/embj.2019103790CrossRef

106.

Monje, M. L., Mizumatsu, S., Fike, J. R., & Palmer, T. D. (2002). Irradiation induces neural precursor-cell dysfunction. Nature Medicine, 8(9), 955–962. https://doi.org/10.1038/nm749CrossRef

107.

Gibson, E. M., Nagaraja, S., Ocampo, A., Tam, L. T., Wood, L. S., Pallegar, P. N., & Monje, M. (2019). Methotrexate chemotherapy induces persistent tri-glial dysregulation that underlies chemotherapy-related cognitive impairment. Cell, 176(1–2), 43-55.e13. https://doi.org/10.1016/j.cell.2018.10.049CrossRef

108.

Prionisti, I., Bühler, L. H., Walker, P. R., & Jolivet, R. B. (2019). Harnessing microglia and macrophages for the treatment of glioblastoma. Frontiers in Pharmacology, 10, 506. https://doi.org/10.3389/fphar.2019.00506CrossRef

109.

Mrdjen, D., Pavlovic, A., Hartmann, F. J., Schreiner, B., Utz, S. G., Leung, B. P., & Becher, B. (2018). High-dimensional single-cell mapping of central nervous system immune cells reveals distinct myeloid subsets in health, aging, and disease. Immunity, 48(3), 599. https://doi.org/10.1016/j.immuni.2018.02.014CrossRef

110.

Imai, Y., & Kohsaka, S. (2002). Intracellular signaling in M-CSF-induced microglia activation: Role of Iba1. Glia, 40(2), 164–174. https://doi.org/10.1002/glia.10149CrossRef

111.

Sasaki, A. (2017). Microglia and brain macrophages: An update. Neuropathology, 37(5), 452–464. https://doi.org/10.1111/neup.12354CrossRef

112.

Ghosh, S., Castillo, E., Frias, E. S., & Swanson, R. A. (2018). Bioenergetic regulation of microglia. Glia, 66(6), 1200–1212. https://doi.org/10.1002/glia.23271CrossRef

113.

Hume, D. A., & MacDonald, K. P. (2012). Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood, 119(8), 1810–1820. https://doi.org/10.1182/blood-2011-09-379214CrossRef

114.

Jones, C. V., & Ricardo, S. D. (2013). Macrophages and CSF-1: Implications for development and beyond. Organogenesis, 9(4), 249–260. https://doi.org/10.4161/org.25676CrossRef

115.

Guilliams, M., Thierry, G. R., Bonnardel, J., & Bajenoff, M. (2020). Establishment and maintenance of the macrophage niche. Immunity, 52(3), 434–451. https://doi.org/10.1016/j.immuni.2020.02.015CrossRef

116.

Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., & Joyce, J. A. (2013). CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nature Medicine, 19(10), 1264–1272. https://doi.org/10.1038/nm.3337CrossRef

117.

Quail, D. F., Bowman, R. L., Akkari, L., Quick, M. L., Schuhmacher, A. J., Huse, J. T., & Joyce, J. A. (2016). The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science, 352(6288), aad3018. https://doi.org/10.1126/science.aad3018CrossRef

118.

Butowski, N., Colman, H., De Groot, J. F., Omuro, A. M., Nayak, L., Wen, P. Y., & Prados, M. (2016). Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: An Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-Oncology, 18(4), 557–564. https://doi.org/10.1093/neuonc/nov245CrossRef

119.

Ries, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., & Rüttinger, D. (2014). Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell, 25(6), 846–859. https://doi.org/10.1016/j.ccr.2014.05.016CrossRef

120.

Tap, W. D., Wainberg, Z. A., Anthony, S. P., Ibrahim, P. N., Zhang, C., Healey, J. H., & Bollag, G. (2015). Structure-guided nlockade of CSF1R kinase in tenosynovial giant-cell tumor. New England Journal of Medicine, 373(5), 428–437. https://doi.org/10.1056/NEJMoa1411366CrossRef

121.

Autio, K. A., Klebanoff, C. A., Schaer, D., Kauh, J. S. W., Slovin, S. F., Adamow, M., & McArthur, H. L. (2020). Immunomodulatory activity of a colony-stimulating factor-1 receptor inhibitor in patients with advanced refractory breast or prostate cancer: A phase I study. Clinical Cancer Research, 26(21), 5609–5620. https://doi.org/10.1158/1078-0432.CCR-20-0855CrossRef

122.

Akkari, L., Bowman, R. L., Tessier, J., Klemm, F., Handgraaf, S. M., de Groot, M., Joyce, J. A. (2020). Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance. Scencei Translational Medicine, 12(552). https://doi.org/10.1126/scitranslmed.aaw7843

123.

Boring, L., Gosling, J., Chensue, S. W., Kunkel, S. L., Farese, R. V., Broxmeyer, H. E., & Charo, I. F. (1997). Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. The Journal of Clinical Investigation, 100(10), 2552–2561. https://doi.org/10.1172/JCI119798CrossRef

124.

Felsenstein, M., Blank, A., Bungert, A. D., Mueller, A., Ghori, A., Kremenetskaia, I., Brandenburg, S. (2020). CCR2 of tumor microenvironmental cells is a relevant modulator of glioma biology. Cancers (Basel), 12(7). https://doi.org/10.3390/cancers12071882

125.

Flores-Toro, J. A., Luo, D., Gopinath, A., Sarkisian, M. R., Campbell, J. J., Charo, I. F., & Harrison, J. K. (2020). CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas. Proc Natl Acad Sci U S A, 117(2), 1129–1138. https://doi.org/10.1073/pnas.1910856117CrossRef

126.

Saha, D., Martuza, R. L., & Rabkin, S. D. (2017). Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade. Cancer Cell, 32(2), 253-267.e255. https://doi.org/10.1016/j.ccell.2017.07.006CrossRef

127.

Banchereau, J., & Steinman, R. M. (1998). Dendritic cells and the control of immunity. Nature, 392(6673), 245–252. https://doi.org/10.1038/32588CrossRef

128.

Steinman, R. M., & Banchereau, J. (2007). Taking dendritic cells into medicine. Nature, 449(7161), 419–426. https://doi.org/10.1038/nature06175CrossRef

129.

Steinman, R. M. (2012). Decisions about dendritic cells: Past, present, and future. Annual Review of Immunology, 30, 1–22. https://doi.org/10.1146/annurev-immunol-100311-102839CrossRef

130.

Shortman, K., & Naik, S. H. (2007). Steady-state and inflammatory dendritic-cell development. Nature Reviews Immunology, 7(1), 19–30. https://doi.org/10.1038/nri1996CrossRef

131.

Hashimoto, D., Miller, J., & Merad, M. (2011). Dendritic cell and macrophage heterogeneity in vivo. Immunity, 35(3), 323–335. https://doi.org/10.1016/j.immuni.2011.09.007CrossRef

132.

Palucka, K., & Banchereau, J. (2012). Cancer immunotherapy via dendritic cells. Nature Reviews Cancer, 12(4), 265–277. https://doi.org/10.1038/nrc3258CrossRef

133.

Saxena, M., & Bhardwaj, N. (2018). Re-emergence of dendritic cell vaccines for cancer treatment. Trends Cancer, 4(2), 119–137. https://doi.org/10.1016/j.trecan.2017.12.007CrossRef

134.

Srivastava, S., Jackson, C., Kim, T., Choi, J., & Lim, M. (2019). A characterization of dendritic cells and their role in immunotherapy in glioblastoma: From preclinical studies to clinical trials. Cancers (Basel), 11(4). https://doi.org/10.3390/cancers11040537

135.

Hickey, W. F., & Kimura, H. (1988). Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science, 239(4837), 290–292. https://doi.org/10.1126/science.3276004CrossRef

136.

Ulvestad, E., Williams, K., Bjerkvig, R., Tiekotter, K., Antel, J., & Matre, R. (1994). Human microglial cells have phenotypic and functional characteristics in common with both macrophages and dendritic antigen-presenting cells. Journal of Leukocyte Biology, 56(6), 732–740. https://doi.org/10.1002/jlb.56.6.732CrossRef

137.

Xu, S., Guo, X., Gao, X., Xue, H., Zhang, J., Qiu, W., & Li, G. (2016). Macrophage migration inhibitory factor enhances autophagy by regulating ROCK1 activity and contributes to the escape of dendritic cell surveillance in glioblastoma. International Journal of Oncology, 49(5), 2105–2115. https://doi.org/10.3892/ijo.2016.3704CrossRef

138.

Fadul, C. E., Fisher, J. L., Hampton, T. H., Lallana, E. C., Li, Z., Gui, J., & Ernstoff, M. S. (2011). Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. Journal of Immunotherapy, 34(4), 382–389. https://doi.org/10.1097/CJI.0b013e318215e300CrossRef

139.

Chang, C. N., Huang, Y. C., Yang, D. M., Kikuta, K., Wei, K. J., Kubota, T., & Yang, W. K. (2011). A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma. Journal of Clinical Neuroscience, 18(8), 1048–1054. https://doi.org/10.1016/j.jocn.2010.11.034CrossRef

140.

Ardon, H., Van Gool, S. W., Verschuere, T., Maes, W., Fieuws, S., Sciot, R., & De Vleeschouwer, S. (2012). Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: Results of the HGG-2006 phase I/II trial. Cancer Immunology, Immunotherapy, 61(11), 2033–2044. https://doi.org/10.1007/s00262-012-1261-1CrossRef

141.

Akasaki, Y., Kikuchi, T., Homma, S., Koido, S., Ohkusa, T., Tasaki, T., & Murayama, Y. (2016). Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma. Cancer Immunology, Immunotherapy, 65(12), 1499–1509. https://doi.org/10.1007/s00262-016-1905-7CrossRef

142.

Erhart, F., Buchroithner, J., Reitermaier, R., Fischhuber, K., Klingenbrunner, S., Sloma, I., & Visus, C. (2018). Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: Immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables. Acta Neuropathologica Communications, 6(1), 135. https://doi.org/10.1186/s40478-018-0621-2CrossRef

143.

Inogés, S., Tejada, S., de Cerio, A. L., Gállego Pérez-Larraya, J., Espinós, J., Idoate, M. A., & Valle, R. D. (2017). A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. Journal of Translational Medicine, 15(1), 104. https://doi.org/10.1186/s12967-017-1202-zCrossRef

144.

Hu, J. L., Omofoye, O. A., Rudnick, J. D., Kim, S., Tighiouart, M., Phuphanich, S., & Yu, J. S. (2022). A phase I study of autologous dendritic cell vaccine pulsed with allogeneic stem-like cell line lysate in patients with newly diagnosed or recurrent glioblastoma. Clinical Cancer Research, 28(4), 689–696. https://doi.org/10.1158/1078-0432.CCR-21-2867CrossRef

145.

Wen, P. Y., Reardon, D. A., Armstrong, T. S., Phuphanich, S., Aiken, R. D., Landolfi, J. C., & Yu, J. S. (2019). A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastoma. Clinical Cancer Research, 25(19), 5799–5807. https://doi.org/10.1158/1078-0432.CCR-19-0261CrossRef

146.

Liau, L. M., Ashkan, K., Tran, D. D., Campian, J. L., Trusheim, J. E., Cobbs, C. S., Heth, J. A., Salacz, M., Taylor, S., D’Andre, S. D., Iwamoto, F. M., Dropcho, E. J., Moshel, Y. A., Walter, K. A., Pillainayagam, C. P., Aiken, R., Chaudhary, R., Goldlust, S. A., Bota, D. A., … Bosch, M. L. (2018). First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine innewly diagnosed glioblastoma. J Transl Med., 16(1), 142. https://doi.org/10.1186/s12967-018-1507-6CrossRef

147.

Gordon, S., & Taylor, P. R. (2005). Monocyte and macrophage heterogeneity. Nature Reviews Immunology, 5(12), 953–964. https://doi.org/10.1038/nri1733CrossRef

148.

Shi, C., & Pamer, E. G. (2011). Monocyte recruitment during infection and inflammation. Nature Reviews Immunology, 11(11), 762–774. https://doi.org/10.1038/nri3070CrossRef

149.

Feng, X., Szulzewsky, F., Yerevanian, A., Chen, Z., Heinzmann, D., Rasmussen, R. D., & Hambardzumyan, D. (2015). Loss of CX3CR1 increases accumulation of inflammatory monocytes and promotes gliomagenesis. Oncotarget, 6(17), 15077–15094. https://doi.org/10.18632/oncotarget.3730CrossRef

150.

Shen, C. K., Huang, B. R., Yeh, W. L., Chen, C. W., Liu, Y. S., Lai, S. W., & Tsai, C. F. (2021). Regulatory effects of IL-1β in the interaction of GBM and tumor-associated monocyte through VCAM-1 and ICAM-1. European Journal of Pharmacology, 905, 174216. https://doi.org/10.1016/j.ejphar.2021.174216CrossRef

151.

Chae, M., Peterson, T. E., Balgeman, A., Chen, S., Zhang, L., Renner, D. N., & Parney, I. F. (2015). Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model. Neuro-Oncology, 17(7), 978–991. https://doi.org/10.1093/neuonc/nou343CrossRef

152.

Fadul, C. E., Fisher, J. L., Gui, J., Hampton, T. H., Côté, A. L., & Ernstoff, M. S. (2011). Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro-Oncology, 13(4), 393–400. https://doi.org/10.1093/neuonc/noq204CrossRef

153.

Veglia, F., Perego, M., & Gabrilovich, D. (2018). Myeloid-derived suppressor cells coming of age. Nature Immunology, 19(2), 108–119. https://doi.org/10.1038/s41590-017-0022-xCrossRef

154.

Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012). Coordinated regulation of myeloid cells by tumours. Nature Reviews Immunology, 12(4), 253–268. https://doi.org/10.1038/nri3175CrossRef

155.

Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016). The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends in Immunology, 37(3), 208–220. https://doi.org/10.1016/j.it.2016.01.004CrossRef

156.

Alban, T. J., Alvarado, A. G., Sorensen, M. D., Bayik, D., Volovetz, J., Serbinowski, E., Lathia, J. D. (2018). Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. JCI Insight, 3(21). https://doi.org/10.1172/jci.insight.122264

157.

Raychaudhuri, B., Rayman, P., Ireland, J., Ko, J., Rini, B., Borden, E. C., & Finke, J. (2011). Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro-Oncology, 13(6), 591–599. https://doi.org/10.1093/neuonc/nor042CrossRef

158.

Kamran, N., Chandran, M., Lowenstein, P. R., & Castro, M. G. (2018). Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy. Clinical Immunology, 189, 34–42. https://doi.org/10.1016/j.clim.2016.10.008CrossRef

159.

Dubinski, D., Wölfer, J., Hasselblatt, M., Schneider-Hohendorf, T., Bogdahn, U., Stummer, W., & Grauer, O. M. (2016). CD4⁺ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. Neuro-Oncology, 18(6), 807–818. https://doi.org/10.1093/neuonc/nov280CrossRef

160.

Mirghorbani, M., Van Gool, S., & Rezaei, N. (2013). Myeloid-derived suppressor cells in glioma. Expert Review of Neurotherapeutics, 13(12), 1395–1406. https://doi.org/10.1586/14737175.2013.857603CrossRef

161.

Otvos, B., Silver, D. J., Mulkearns-Hubert, E. E., Alvarado, A. G., Turaga, S. M., Sorensen, M. D., & Lathia, J. D. (2016). Cancer stem cell-secreted macrophage migration inhibitory factor stimulates myeloid derived suppressor cell function and facilitates glioblastoma immune evasion. Stem Cells, 34(8), 2026–2039. https://doi.org/10.1002/stem.2393CrossRef

162.

Alban, T. J., Bayik, D., Otvos, B., Rabljenovic, A., Leng, L., Jia-Shiun, L., & Lathia, J. D. (2020). Glioblastoma myeloid-derived suppressor cell subsets express differential macrophage migration inhibitory factor receptor profiles that can be targeted to reduce immune suppression. Frontiers in Immunology, 11, 1191. https://doi.org/10.3389/fimmu.2020.01191CrossRef

163.

Ostrom, Q. T., Kinnersley, B., Wrensch, M. R., Eckel-Passow, J. E., Armstrong, G., Rice, T., & consortium, G,. (2018). Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21. Sci Rep, 8(1), 7352. https://doi.org/10.1038/s41598-018-24580-zCrossRef

164.

Kamran, N., Kadiyala, P., Saxena, M., Candolfi, M., Li, Y., Moreno-Ayala, M. A., & Castro, M. G. (2017). Immunosuppressive myeloid cells’ blockade in the glioma microenvironment enhances the efficacy of immune-stimulatory gene therapy. Molecular Therapy, 25(1), 232–248. https://doi.org/10.1016/j.ymthe.2016.10.003CrossRef

165.

Nars, M. S., & Kaneno, R. (2013). Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy. International Journal of Cancer, 132(11), 2471–2478. https://doi.org/10.1002/ijc.27801CrossRef

166.

Peereboom, D. M., Alban, T. J., Grabowski, M. M., Alvarado, A. G., Otvos, B., Bayik, D., Lathia, J. D. (2019). Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells. JCI Insight, 4(22). https://doi.org/10.1172/jci.insight.130748

167.

Giese, M. A., Hind, L. E., & Huttenlocher, A. (2019). Neutrophil plasticity in the tumor microenvironment. Blood, 133(20), 2159–2167. https://doi.org/10.1182/blood-2018-11-844548CrossRef

168.

Wculek, S. K., & Malanchi, I. (2015). Neutrophils support lung colonization of metastasis-initiating breast cancer cells. Nature, 528(7582), 413–417. https://doi.org/10.1038/nature16140CrossRef

169.

Wang, Q., Hu, B., Hu, X., Kim, H., Squatrito, M., Scarpace, L., & Verhaak, R. G. W. (2017). Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell, 32(1), 42-56.e46. https://doi.org/10.1016/j.ccell.2017.06.003CrossRef

170.

Bambury, R. M., Teo, M. Y., Power, D. G., Yusuf, A., Murray, S., Battley, J. E., & O’Reilly, S. (2013). The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme. Journal of Neuro-oncology, 114(1), 149–154. https://doi.org/10.1007/s11060-013-1164-9CrossRef

171.

Mason, M., Maurice, C., McNamara, M. G., Tieu, M. T., Lwin, Z., Millar, B. A., & Chung, C. (2017). Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival. Journal of Neuro-oncology, 132(3), 463–471. https://doi.org/10.1007/s11060-017-2395-yCrossRef

172.

Massara, M., Persico, P., Bonavita, O., Mollica Poeta, V., Locati, M., Simonelli, M., & Bonecchi, R. (2017). Neutrophils in gliomas. Frontier in Immunology, 8, 1349. https://doi.org/10.3389/fimmu.2017.01349CrossRef

173.

Hor, W. S., Huang, W. L., Lin, Y. S., & Yang, B. C. (2003). Cross-talk between tumor cells and neutrophils through the Fas (APO-1, CD95)/FasL system: Human glioma cells enhance cell viability and stimulate cytokine production in neutrophils. Journal of Leukocyte Biology, 73(3), 363–368. https://doi.org/10.1189/jlb.0702375CrossRef

174.

Chio, C. C., Wang, Y. S., Chen, Y. L., Lin, S. J., & Yang, B. C. (2001). Down-regulation of Fas-L in glioma cells by ribozyme reduces cell apoptosis, tumour-infiltrating cells, and liver damage but accelerates tumour formation in nude mice. British Journal of Cancer, 85(8), 1185–1192. https://doi.org/10.1054/bjoc.2001.2055CrossRef

175.

Sampson, J. H., Gunn, M. D., Fecci, P. E., & Ashley, D. M. (2020). Brain immunology and immunotherapy in brain tumours. Nature Reviews Cancer, 20(1), 12–25. https://doi.org/10.1038/s41568-019-0224-7CrossRef

176.

Iwatsuki, K., Kumara, E., Yoshimine, T., Nakagawa, H., Sato, M., & Hayakawa, T. (2000). Elastase expression by infiltrating neutrophils in gliomas. Neurological Research, 22(5), 465–468. https://doi.org/10.1080/01616412.2000.11740701CrossRef

177.

Chow, K. H., Park, H. J., George, J., Yamamoto, K., Gallup, A. D., Graber, J. H., & Yun, K. (2017). S100A4 is a biomarker and regulator of glioma stem cells that is critical for mesenchymal transition in glioblastoma. Cancer Research, 77(19), 5360–5373. https://doi.org/10.1158/0008-5472.CAN-17-1294CrossRef

178.

Lee, S. Y., Kim, J. K., Jeon, H. Y., Ham, S. W., & Kim, H. (2017). CD133 Regulates IL-1β signaling and neutrophil recruitment in glioblastoma. Molecules and Cells, 40(7), 515–522. https://doi.org/10.14348/molcells.2017.0089CrossRef

179.

Sippel, T. R., White, J., Nag, K., Tsvankin, V., Klaassen, M., Kleinschmidt-DeMasters, B. K., & Waziri, A. (2011). Neutrophil degranulation and immunosuppression in patients with GBM: Restoration of cellular immune function by targeting arginase I. Clinical Cancer Research, 17(22), 6992–7002. https://doi.org/10.1158/1078-0432.CCR-11-1107CrossRef

180.

Fossati, G., Ricevuti, G., Edwards, S. W., Walker, C., Dalton, A., & Rossi, M. L. (1999). Neutrophil infiltration into human gliomas. Acta Neuropathologica, 98(4), 349–354. https://doi.org/10.1007/s004010051093CrossRef

181.

Zha, C., Meng, X., Li, L., Mi, S., Qian, D., Li, Z., & Liu, Y. (2020). Neutrophil extracellular traps mediate the crosstalk between glioma progression and the tumor microenvironment. Cancer Biology and Medicine, 17(1), 154–16. https://doi.org/10.20892/j.issn.2095-3941.2019.0353CrossRef

182.

Mayadas, T. N., Cullere, X., & Lowell, C. A. (2014). The multifaceted functions of neutrophils. Annual Review of Pathology: Mechanisms of Disease, 9, 181–218. https://doi.org/10.1146/annurev-pathol-020712-164023CrossRef

183.

Albrengues, J., Shields, M. A., Ng, D., Park, C. G., Ambrico, A., Poindexter, M. E., Egeblad, M. (2018). Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science, 361(6409). https://doi.org/10.1126/science.aao4227

184.

Park, J., Wysocki, R. W., Amoozgar, Z., Maiorino, L., Fein, M. R., Jorns, J., Egeblad, M. (2016). Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps. Sci Transl Med, 8(361), 361ra138. https://doi.org/10.1126/scitranslmed.aag1711

185.

Yee, P. P., Wei, Y., Kim, S. Y., Lu, T., Chih, S. Y., Lawson, C., & Li, W. (2020). Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression. Nature Communications, 11(1), 5424. https://doi.org/10.1038/s41467-020-19193-yCrossRef

186.

Liang, J., Piao, Y., Holmes, L., Fuller, G. N., Henry, V., Tiao, N., & de Groot, J. F. (2014). Neutrophils promote the malignant glioma phenotype through S100A4. Clinical Cancer Research, 20(1), 187–198. https://doi.org/10.1158/1078-0432.CCR-13-1279CrossRef

187.

Donskov, F. (2013). Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Seminars in Cancer Biology, 23(3), 200–207. https://doi.org/10.1016/j.semcancer.2013.02.001CrossRef

188.

Rahbar, A., Cederarv, M., Wolmer-Solberg, N., Tammik, C., Stragliotto, G., Peredo, I., & Söderberg-Nauclér, C. (2016). Enhanced neutrophil activity is associated with shorter time to tumor progression in glioblastoma patients. Oncoimmunology, 5(2), e1075693. https://doi.org/10.1080/2162402X.2015.1075693CrossRef

189.

McNamara, M. G., Lwin, Z., Jiang, H., Templeton, A. J., Zadeh, G., Bernstein, M., & Mason, W. P. (2014). Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression. Journal of Neuro-oncology, 117(1), 147–152. https://doi.org/10.1007/s11060-014-1366-9CrossRef

190.

Haksoyler, V., Besen, A., & A., Koseci, T., Olgun, P., Bayram, E., & Topkan, E. (2021). Neutrophil-to-lymphocyte ratio is prognostic in recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan. Biomarkers in Medicine, 15(11), 851–859. https://doi.org/10.2217/bmm-2021-0271CrossRef

191.

Bertaut, A., Truntzer, C., Madkouri, R., Kaderbhai, C. G., Derangère, V., Vincent, J., & Ghiringhelli, F. (2016). Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma. Oncotarget, 7(43), 70948–70958. https://doi.org/10.18632/oncotarget.10898CrossRef

192.

Fujita, M., Scheurer, M. E., Decker, S. A., McDonald, H. A., Kohanbash, G., Kastenhuber, E. R., & Okada, H. (2010). Role of type 1 IFNs in antiglioma immunosurveillance–using mouse studies to guide examination of novel prognostic markers in humans. Clinical Cancer Research, 16(13), 3409–3419. https://doi.org/10.1158/1078-0432.CCR-10-0644CrossRef

193.

Quillien, V., Carpentier, A. F., Gey, A., Avril, T., Tartour, E., Sejalon, F., & Vauleon, E. (2019). Absolute numbers of regulatory T cells and neutrophils in corticosteroid-free patients are predictive for response to bevacizumab in recurrent glioblastoma patients. Cancer Immunology, Immunotherapy, 68(6), 871–882. https://doi.org/10.1007/s00262-019-02317-9CrossRef

194.

Anderson, K. G., Stromnes, I. M., & Greenberg, P. D. (2017). Obstacles posed by the tumor microenvironment to T cell activity: A case for synergistic therapies. Cancer Cell, 31(3), 311–325. https://doi.org/10.1016/j.ccell.2017.02.008CrossRef

195.

Crespo, J., Sun, H., Welling, T. H., Tian, Z., & Zou, W. (2013). T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Current Opinion in Immunology, 25(2), 214–221. https://doi.org/10.1016/j.coi.2012.12.003CrossRef

196.

Speiser, D. E., Ho, P. C., & Verdeil, G. (2016). Regulatory circuits of T cell function in cancer. Nature Reviews Immunology, 16(10), 599–611. https://doi.org/10.1038/nri.2016.80CrossRef

197.

Wherry, E. J., & Kurachi, M. (2015). Molecular and cellular insights into T cell exhaustion. Nature Reviews Immunology, 15(8), 486–499. https://doi.org/10.1038/nri3862CrossRef

198.

Brooks, W. H., Roszman, T. L., Mahaley, M. S., & Woosley, R. E. (1977). Immunobiology of primary intracranial tumours. II. Analysis of lymphocyte subpopulations in patients with primary brain tumours. Clinical and Experimentel Immunology, 29(1), 61–66.

199.

Chongsathidkiet, P., Jackson, C., Koyama, S., Loebel, F., Cui, X., Farber, S. H., & Fecci, P. E. (2018). Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nature Medicine, 24(9), 1459–1468. https://doi.org/10.1038/s41591-018-0135-2CrossRef

200.

Sharma, P., & Allison, J. P. (2015). The future of immune checkpoint therapy. Science, 348(6230), 56–61. https://doi.org/10.1126/science.aaa8172CrossRef

201.

Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., & Getz, G. (2013). Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature, 499(7457), 214–218. https://doi.org/10.1038/nature12213CrossRef

202.

Reardon, D. A., Brandes, A. A., Omuro, A., Mulholland, P., Lim, M., Wick, A., & Weller, M. (2020). Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: The CheckMate 143 phase 3 randomized clinical trial. JAMA Oncology, 6(7), 1003–1010. https://doi.org/10.1001/jamaoncol.2020.1024CrossRef

203.

Woroniecka, K., & Fecci, P. E. (2020). Immuno-synergy? Neoantigen vaccines and checkpoint blockade in glioblastoma. Neuro-Oncology, 22(9), 1233–1234. https://doi.org/10.1093/neuonc/noaa170CrossRef

204.

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., & Chan, T. A. (2015). Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science, 348(6230), 124–128. https://doi.org/10.1126/science.aaa1348CrossRef

205.

Mirzaei, R., Sarkar, S., & Yong, V. W. (2017). T cell exhaustion in glioblastoma: Intricacies of immune checkpoints. Trends in Immunology, 38(2), 104–115. https://doi.org/10.1016/j.it.2016.11.005CrossRef

206.

Ravi, V. M., Neidert, N., Will, P., Joseph, K., Maier, J. P., Kückelhaus, J., & Heiland, D. H. (2022). T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10. Nature Communications, 13(1), 925. https://doi.org/10.1038/s41467-022-28523-1CrossRef

207.

Zhao, J., Chen, A. X., Gartrell, R. D., Silverman, A. M., Aparicio, L., Chu, T., & Rabadan, R. (2019). Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nature Medicine, 25(3), 462–469. https://doi.org/10.1038/s41591-019-0349-yCrossRef

208.

Cham, C. M., Driessens, G., O’Keefe, J. P., & Gajewski, T. F. (2008). Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells. European Journal of Immunology, 38(9), 2438–2450. https://doi.org/10.1002/eji.200838289CrossRef

209.

Chang, C. H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., & Pearce, E. L. (2015). Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell, 162(6), 1229–1241. https://doi.org/10.1016/j.cell.2015.08.016CrossRef

210.

Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Bergers, G. (2017). Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med, 9(385). https://doi.org/10.1126/scitranslmed.aak9679

211.

Sadelain, M., Rivière, I., & Riddell, S. (2017). Therapeutic T cell engineering. Nature, 545(7655), 423–431. https://doi.org/10.1038/nature22395CrossRef

212.

Majzner, R. G., & Mackall, C. L. (2019). Clinical lessons learned from the first leg of the CAR T cell journey. Nature Medicine, 25(9), 1341–1355. https://doi.org/10.1038/s41591-019-0564-6CrossRef

213.

Turtle, C. J., Hanafi, L. A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., & Maloney, D. G. (2016). CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. The Journal of Clinical Investigation, 126(6), 2123–2138. https://doi.org/10.1172/JCI85309CrossRef

214.

Bagley, S. J., Desai, A. S., Linette, G. P., June, C. H., & O’Rourke, D. M. (2018). CAR T-cell therapy for glioblastoma: Recent clinical advances and future challenges. Neuro-Oncology, 20(11), 1429–1438. https://doi.org/10.1093/neuonc/noy032CrossRef

215.

Sarah, C. (2017). Immunotherapy: CAR T cells in glioblastoma. Nature Reviews. Drug Discovery, 16(9), 602. https://doi.org/10.1038/nrd.2017.158CrossRef

216.

Brown, C. E., Badie, B., Barish, M. E., Weng, L., Ostberg, J. R., Chang, W. C., & Jensen, M. C. (2015). Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clinical Cancer Research, 21(18), 4062–4072. https://doi.org/10.1158/1078-0432.CCR-15-0428CrossRef

217.

Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., & Badie, B. (2016). Regression of glioblastoma after chimeric antigen receptor T-cell therapy. New England Journal of Medicine, 375(26), 2561–2569. https://doi.org/10.1056/NEJMoa1610497CrossRef

218.

Karachi, A., Dastmalchi, F., Nazarian, S., Huang, J., Sayour, E. J., Jin, L., & Rahman, M. (2021). Optimizing T cell-based therapy for glioblastoma. Frontiers in Immunology, 12, 705580. https://doi.org/10.3389/fimmu.2021.705580CrossRef

219.

Ahmed, N., Brawley, V., Hegde, M., Bielamowicz, K., Kalra, M., Landi, D., & Gottschalk, S. (2017). HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: A phase 1 dose-escalation trial. JAMA Oncology, 3(8), 1094–1101. https://doi.org/10.1001/jamaoncol.2017.0184CrossRef

220.

O'Rourke, D. M., Nasrallah, M. P., Desai, A., Melenhorst, J. J., Mansfield, K., Morrissette, J. J. D., Maus, M. V. (2017). A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med, 9(399). https://doi.org/10.1126/scitranslmed.aaa0984

221.

An, Z., Hu, Y., Bai, Y., Zhang, C., Xu, C., Kang, X., & Zhong, X. (2021). Antitumor activity of the third generation EphA2 CAR-T cells against glioblastoma is associated with interferon gamma induced PD-L1. Oncoimmunology, 10(1), 1960728. https://doi.org/10.1080/2162402X.2021.1960728CrossRef

222.

Lin, Q., Ba, T., Ho, J., Chen, D., Cheng, Y., Wang, L., & Ling, F. (2021). First-in-human trial of EphA2-redirected CAR T-cells in patients with recurrent glioblastoma: A preliminary report of three cases at the starting dose. Frontiers in Oncology, 11, 694941. https://doi.org/10.3389/fonc.2021.694941CrossRef

223.

Rousso-Noori, L., Mastandrea, I., Talmor, S., Waks, T., Globerson Levin, A., Haugas, M., & Friedmann-Morvinski, D. (2021). P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas. Nature Communications, 12(1), 3615. https://doi.org/10.1038/s41467-021-23817-2CrossRef

224.

Murty, S., Haile, S. T., Beinat, C., Aalipour, A., Alam, I. S., Murty, T., & Gambhir, S. S. (2020). Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model. Oncoimmunology, 9(1), 1757360. https://doi.org/10.1080/2162402X.2020.1757360CrossRef

225.

Golinelli, G., Grisendi, G., Prapa, M., Bestagno, M., Spano, C., Rossignoli, F., & Dominici, M. (2020). Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors. Cancer Gene Therapy, 27(7–8), 558–570. https://doi.org/10.1038/s41417-018-0062-xCrossRef

226.

Li, G., Zhang, Z., Cai, L., Tang, X., Huang, J., Yu, L., & Zhou, L. (2021). Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma. Oncoimmunology, 10(1), 1983306. https://doi.org/10.1080/2162402X.2021.1983306CrossRef

227.

Tang, X., Zhao, S., Zhang, Y., Wang, Y., Zhang, Z., Yang, M., & Zhou, L. (2019). B7–H3 as a novel CAR-T therapeutic target for glioblastoma. Mol Ther Oncolytics, 14, 279–287. https://doi.org/10.1016/j.omto.2019.07.002CrossRef

228.

Barrow, A. D., Edeling, M. A., Trifonov, V., Luo, J., Goyal, P., Bohl, B., & Colonna, M. (2018). Natural killer cells control tumor growth by sensing a growth factor. Cell, 172(3), 534-548.e519. https://doi.org/10.1016/j.cell.2017.11.037CrossRef

229.

Chiossone, L., Dumas, P. Y., Vienne, M., & Vivier, E. (2018). Natural killer cells and other innate lymphoid cells in cancer. Nature Reviews Immunology, 18(11), 671–688. https://doi.org/10.1038/s41577-018-0061-zCrossRef

230.

Fu, W., Wang, W., Li, H., Jiao, Y., Huo, R., Yan, Z., & Zhao, J. (2020). Single-cell atlas reveals complexity of the immunosuppressive microenvironment of initial and recurrent glioblastoma. Frontiers in Immunology, 11, 835. https://doi.org/10.3389/fimmu.2020.00835CrossRef

231.

Wendel, M., Galani, I. E., Suri-Payer, E., & Cerwenka, A. (2008). Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Research, 68(20), 8437–8445. https://doi.org/10.1158/0008-5472.CAN-08-1440CrossRef

232.

Bielamowicz, K., Khawja, S., & Ahmed, N. (2013). Adoptive cell therapies for glioblastoma. Frontiers in Oncology, 3, 275. https://doi.org/10.3389/fonc.2013.00275CrossRef

233.

Golán, I., Rodríguez de la Fuente, L., & Costoya, J. A. (2018). NK cell-based glioblastoma immunotherapy. Cancers (Basel), 10(12). https://doi.org/10.3390/cancers10120522

234.

Kmiecik, J., Zimmer, J., & Chekenya, M. (2014). Natural killer cells in intracranial neoplasms: Presence and therapeutic efficacy against brain tumours. Journal of Neuro-oncology, 116(1), 1–9. https://doi.org/10.1007/s11060-013-1265-5CrossRef

235.

Alvarez-Breckenridge, C. A., Yu, J., Caligiuri, M. A., & Chiocca, E. A. (2013). Uncovering a novel mechanism whereby NK cells interfere with glioblastoma virotherapy. Oncoimmunology, 2(4), e23658. https://doi.org/10.4161/onci.23658CrossRef

236.

Xu, B., Ma, R., Russell, L., Yoo, J. Y., Han, J., Cui, H., Yu, J. (2018). An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma. Nature Biotechnologyhttps://doi.org/10.1038/nbt.4302

237.

Ishikawa, E., Tsuboi, K., Saijo, K., Harada, H., Takano, S., Nose, T., & Ohno, T. (2004). Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Research, 24(3b), 1861–1871.

238.

Höring, E., Podlech, O., Silkenstedt, B., Rota, I. A., Adamopoulou, E., & Naumann, U. (2013). The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells. Anticancer Research, 33(4), 1351–1360.

239.

Gras Navarro, A., Espedal, H., Joseph, J. V., Trachsel-Moncho, L., Bahador, M., Gjertsen, B. T., Chekenya, M. (2019). Pretreatment of glioblastoma with bortezomib potentiates natural killer cell cytotoxicity through TRAIL/DR5 mediated apoptosis and prolongs animal survival. Cancers (Basel), 11(7). https://doi.org/10.3390/cancers11070996

240.

Kmiecik, J., Gras Navarro, A., Poli, A., Planagumà, J. P., & ChekenyaZimmer, J. M. (2014). Combining NK cells and mAb9227 to combat NG2-dependent and anti-inflammatory signals in glioblastoma. Oncoimmunology, 3(1), e27185. https://doi.org/10.4161/onci.27185CrossRef

241.

Thiruchelvam-Kyle, L., Hoelsbrekken, S. E., Saether, P. C., Bjørnsen, E. G., Pende, D., Fossum, S., & Dissen, E. (2017). The activating human NK cell receptor KIR2DS2 recognizes a β. The Journal of Immunology, 198(7), 2556–2567. https://doi.org/10.4049/jimmunol.1600930CrossRef

242.

Gras Navarro, A., Kmiecik, J., Leiss, L., Zelkowski, M., Engelsen, A., Bruserud, Ø., & Chekenya, M. (2014). NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival. The Journal of Immunology, 193(12), 6192–6206. https://doi.org/10.4049/jimmunol.1400859CrossRef

243.

Burger, M. C., Zhang, C., Harter, P. N., Romanski, A., Strassheimer, F., Senft, C., & Wels, W. S. (2019). CAR-engineered NK cells for the treatment of glioblastoma: Turning innate effectors into precision tools for cancer immunotherapy. Frontiers in Immunology, 10, 2683. https://doi.org/10.3389/fimmu.2019.02683CrossRef

244.

Genßler, S., Burger, M. C., Zhang, C., Oelsner, S., Mildenberger, I., Wagner, M., & Wels, W. S. (2016). Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival. Oncoimmunology, 5(4), e1119354. https://doi.org/10.1080/2162402X.2015.1119354CrossRef

245.

Murakami, T., Nakazawa, T., Natsume, A., Nishimura, F., Nakamura, M., Matsuda, R., & Nakase, H. (2018). Novel human NK cell line carrying CAR targeting EGFRvIII induces antitumor effects in glioblastoma cells. Anticancer Res, 38(9), 5049–5056. https://doi.org/10.21873/anticanres.12824CrossRef

246.

Zhang, C., Burger, M. C., Jennewein, L., Genßler, S., Schönfeld, K., Zeiner, P., Wels, W. S. (2016). ErbB2/HER2-specific NK cells for targeted therapy of glioblastoma. J Natl Cancer Inst, 108(5). https://doi.org/10.1093/jnci/djv375

247.

Zhang, C., Oberoi, P., Oelsner, S., Waldmann, A., Lindner, A., Tonn, T., & Wels, W. S. (2017). Chimeric antigen receptor-engineered NK-92 cells: An off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity. Frontiers in Immunology, 8, 533. https://doi.org/10.3389/fimmu.2017.00533CrossRef

248.

Lupo, K. B., & Matosevic, S. (2020). CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma. Journal of Hematology & Oncology, 13(1), 76. https://doi.org/10.1186/s13045-020-00913-2CrossRef

249.

Haspels, H. N., Rahman, M. A., Joseph, J. V., Gras Navarro, A., & Chekenya, M. (2018). Glioblastoma stem-like cells are more susceptible than differentiated cells to natural killer cell lysis mediated through killer immunoglobulin-like receptors-human leukocyte antigen ligand mismatch and activation receptor-ligand interactions. Frontiers in Immunology, 9, 1345. https://doi.org/10.3389/fimmu.2018.01345CrossRef

250.

Lan, X., Jörg, D. J., Cavalli, F. M. G., Richards, L. M., Nguyen, L. V., Vanner, R. J., & Dirks, P. B. (2017). Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy. Nature, 549(7671), 227–232. https://doi.org/10.1038/nature23666CrossRef

251.

Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., & Dirks, P. B. (2004). Identification of human brain tumour initiating cells. Nature, 432(7015), 396–401. https://doi.org/10.1038/nature03128CrossRef

252.

Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., & Rich, J. N. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444(7120), 756–760. https://doi.org/10.1038/nature05236CrossRef

253.

Chen, J., Li, Y., Yu, T. S., McKay, R. M., Burns, D. K., Kernie, S. G., & Parada, L. F. (2012). A restricted cell population propagates glioblastoma growth after chemotherapy. Nature, 488(7412), 522–526. https://doi.org/10.1038/nature11287CrossRef

254.

Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., & Bernstein, B. E. (2014). Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science, 344(6190), 1396–1401. https://doi.org/10.1126/science.1254257CrossRef

255.

Stiles, C. D., & Rowitch, D. H. (2008). Glioma stem cells: A midterm exam. Neuron, 58(6), 832–846. https://doi.org/10.1016/j.neuron.2008.05.031CrossRef

256.

Couturier, C. P., Ayyadhury, S., Le, P. U., Nadaf, J., Monlong, J., Riva, G., & Petrecca, K. (2020). Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy. Nature Communications, 11(1), 3406. https://doi.org/10.1038/s41467-020-17186-5CrossRef

257.

Ben-Porath, I., Thomson, M. W., Carey, V. J., Ge, R., Bell, G. W., Regev, A., & Weinberg, R. A. (2008). An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nature Genetics, 40(5), 499–507. https://doi.org/10.1038/ng.127CrossRef

258.

Shibue, T., & Weinberg, R. A. (2017). EMT, CSCs, and drug resistance: The mechanistic link and clinical implications. Nature Reviews. Clinical Oncology, 14(10), 611–629. https://doi.org/10.1038/nrclinonc.2017.44CrossRef

259.

Shahcheraghi, S. H., Tchokonte-Nana, V., Lotfi, M., Ghorbani, A., & Sadeghnia, H. R. (2020). Wnt/beta-catenin and PI3K/Akt/mTOR signaling pathways in glioblastoma: Two main targets for drug design: A review. Current Pharmaceutical Design, 26(15), 1729–1741. https://doi.org/10.2174/1381612826666200131100630CrossRef

260.

Gronych, J., Pfister, S. M., & Jones, D. T. (2014). Connect four with glioblastoma stem cell factors. Cell, 157(3), 525–527. https://doi.org/10.1016/j.cell.2014.04.001CrossRef

261.

Neftel, C., Laffy, J., Filbin, M. G., Hara, T., Shore, M. E., Rahme, G. J., & Suvà, M. L. (2019). An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell, 178(4), 835-849.e821. https://doi.org/10.1016/j.cell.2019.06.024CrossRef

262.

Hubert, C. G., & Lathia, J. D. (2021). Seeing the GBM diversity spectrum. Nat Cancer, 2(2), 135–137. https://doi.org/10.1038/s43018-021-00176-xCrossRef

263.

Kreso, A., & Dick, J. E. (2014). Evolution of the cancer stem cell model. Cell Stem Cell, 14(3), 275–291. https://doi.org/10.1016/j.stem.2014.02.006CrossRef

264.

Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017). Epigenetic plasticity and the hallmarks of cancer. Science, 357(6348). https://doi.org/10.1126/science.aal2380

265.

Suvà, M. L., Riggi, N., & Bernstein, B. E. (2013). Epigenetic reprogramming in cancer. Science, 339(6127), 1567–1570. https://doi.org/10.1126/science.1230184CrossRef

266.

Wang, X., Zhou, R., Xiong, Y., Zhou, L., Yan, X., Wang, M., & Wang, Y. (2021). Sequential fate-switches in stem-like cells drive the tumorigenic trajectory from human neural stem cells to malignant glioma. Cell Research, 31(6), 684–702. https://doi.org/10.1038/s41422-020-00451-zCrossRef

267.

Verhaak, R. G., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., & Network, C. G. A. R. (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 17(1), 98–110. https://doi.org/10.1016/j.ccr.2009.12.020CrossRef

268.

Sottoriva, A., Spiteri, I., Piccirillo, S. G., Touloumis, A., Collins, V. P., Marioni, J. C., & Tavaré, S. (2013). Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A, 110(10), 4009–4014. https://doi.org/10.1073/pnas.1219747110CrossRef

269.

Wang, J., Xu, S. L., Duan, J. J., Yi, L., Guo, Y. F., Shi, Y., & Yu, S. C. (2019). Invasion of white matter tracts by glioma stem cells is regulated by a NOTCH1-SOX2 positive-feedback loop. Nature Neuroscience, 22(1), 91–105. https://doi.org/10.1038/s41593-018-0285-zCrossRef

270.

Yi, L., Zhou, X., Li, T., Liu, P., Hai, L., Tong, L., & Yang, X. (2019). Notch1 signaling pathway promotes invasion, self-renewal and growth of glioma initiating cells via modulating chemokine system CXCL12/CXCR4. Journal of Experimental & Clinical Cancer Research, 38(1), 339. https://doi.org/10.1186/s13046-019-1319-4CrossRef

271.

Rusu, P., Shao, C., Neuerburg, A., Acikgöz, A. A., Wu, Y., Zou, P., & Liu, H. K. (2019). GPD1 specifically marks dormant glioma stem cells with a distinct metabolic profile. Cell Stem Cell, 25(2), 241-257.e248. https://doi.org/10.1016/j.stem.2019.06.004CrossRef

272.

Eyler, C. E., Wu, Q., Yan, K., MacSwords, J. M., Chandler-Militello, D., Misuraca, K. L., & Rich, J. N. (2011). Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell, 146(1), 53–66. https://doi.org/10.1016/j.cell.2011.06.006CrossRef

273.

Porčnik, A., Novak, M., Breznik, B., Majc, B., Hrastar, B., Šamec, N., Lah Turnšek, T. (2021). TRIM28 selective nanobody reduces glioblastoma stem cell invasion. Molecules, 26(17). https://doi.org/10.3390/molecules26175141

274.

He, Z. C., Liu, Q., Yang, K. D., Chen, C., Zhang, X. N., Wang, W. Y., & Bian, X. W. (2022). HOXA5 is amplified in glioblastoma stem cells and promotes tumor progression by transcriptionally activating PTPRZ1. Cancer Letters, 533, 215605. https://doi.org/10.1016/j.canlet.2022.215605CrossRef

275.

Marhuenda, E., Fabre, C., Zhang, C., Martin-Fernandez, M., Iskratsch, T., Saleh, A., & Bakalara, N. (2021). Glioma stem cells invasive phenotype at optimal stiffness is driven by MGAT5 dependent mechanosensing. Journal of Experimental & Clinical Cancer Research, 40(1), 139. https://doi.org/10.1186/s13046-021-01925-7CrossRef

276.

Hu, B., Wang, Q., Wang, Y. A., Hua, S., Sauvé, C. G., Ong, D., & DePinho, R. A. (2016). Epigenetic activation of WNT5A drives glioblastoma stem cell differentiation and invasive growth. Cell, 167(5), 1281-1295.e1218. https://doi.org/10.1016/j.cell.2016.10.039CrossRef

277.

Wu, A., Wei, J., Kong, L. Y., Wang, Y., Priebe, W., Qiao, W., & Heimberger, A. B. (2010). Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro-Oncology, 12(11), 1113–1125. https://doi.org/10.1093/neuonc/noq082CrossRef

278.

Wei, J., Barr, J., Kong, L. Y., Wang, Y., Wu, A., Sharma, A. K., & Heimberger, A. B. (2010). Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Molecular Cancer Therapeutics, 9(1), 67–78. https://doi.org/10.1158/1535-7163.MCT-09-0734CrossRef

279.

Esparza, R., Azad, T. D., Feroze, A. H., Mitra, S. S., & Cheshier, S. H. (2015). Glioblastoma stem cells and stem cell-targeting immunotherapies. Journal of Neuro-oncology, 123(3), 449–457. https://doi.org/10.1007/s11060-015-1729-xCrossRef

280.

Taylor, T. E., Furnari, F. B., & Cavenee, W. K. (2012). Targeting EGFR for treatment of glioblastoma: Molecular basis to overcome resistance. Current Cancer Drug Targets, 12(3), 197–209. https://doi.org/10.2174/156800912799277557CrossRef

281.

Hegi, M. E., Rajakannu, P., & Weller, M. (2012). Epidermal growth factor receptor: A re-emerging target in glioblastoma. Current Opinion in Neurology, 25(6), 774–779. https://doi.org/10.1097/WCO.0b013e328359b0bcCrossRef

282.

Solomón, M. T., Selva, J. C., Figueredo, J., Vaquer, J., Toledo, C., Quintanal, N., & Crombet, T. (2013). Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: Results from a randomized, double blind trial. BMC Cancer, 13, 299. https://doi.org/10.1186/1471-2407-13-299CrossRef

283.

Tang, X., Zuo, C., Fang, P., Liu, G., Qiu, Y., Huang, Y., & Tang, R. (2021). Targeting glioblastoma stem cells: A review on biomarkers, signal pathways and targeted therapy. Frontiers in Oncology, 11, 701291. https://doi.org/10.3389/fonc.2021.701291CrossRef

284.

Lv, D., Gimple, R. C., Zhong, C., Wu, Q., Yang, K., Prager, B. C., & Rich, J. N. (2022). PDGF signaling inhibits mitophagy in glioblastoma stem cells through N. Developmental Cell, 57(12), 1466-1481.e1466. https://doi.org/10.1016/j.devcel.2022.05.007CrossRef

285.

Batchelor, T. T., Gerstner, E. R., Ye, X., Desideri, S., Duda, D. G., Peereboom, D., & Supko, J. G. (2017). Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Neuro-Oncology, 19(4), 567–575. https://doi.org/10.1093/neuonc/now185CrossRef

286.

Peñuelas, S., Anido, J., Prieto-Sánchez, R. M., Folch, G., Barba, I., Cuartas, I., & Seoane, J. (2009). TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell, 15(4), 315–327. https://doi.org/10.1016/j.ccr.2009.02.011CrossRef

287.

Kanamori, M., Kawaguchi, T., Nigro, J. M., Feuerstein, B. G., Berger, M. S., Miele, L., & Pieper, R. O. (2007). Contribution of Notch signaling activation to human glioblastoma multiforme. Journal of Neurosurgery, 106(3), 417–427. https://doi.org/10.3171/jns.2007.106.3.417CrossRef

288.

Zheng, H., Ying, H., Wiedemeyer, R., Yan, H., Quayle, S. N., Ivanova, E. V., & DePinho, R. A. (2010). PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell, 17(5), 497–509. https://doi.org/10.1016/j.ccr.2010.03.020CrossRef

289.

Clement, V., Sanchez, P., de Tribolet, N., Radovanovic, I., & Ruiz i Altaba, A. (2007). HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Current Biology, 17(2), 165–172. https://doi.org/10.1016/j.cub.2006.11.033CrossRef

290.

Han, J., Alvarez-Breckenridge, C. A., Wang, Q. E., & Yu, J. (2015). TGF-β signaling and its targeting for glioma treatment. American Journal of Cancer Research, 5(3), 945–955.

291.

Gersey, Z., Osiason, A. D., Bloom, L., Shah, S., Thompson, J. W., Bregy, A., & Komotar, R. J. (2019). Therapeutic targeting of the notch pathway in glioblastoma multiforme. World Neurosurg, 131, 252-263.e252. https://doi.org/10.1016/j.wneu.2019.07.180CrossRef

292.

McCord, M., Mukouyama, Y. S., Gilbert, M. R., & Jackson, S. (2017). Targeting WNT signaling for multifaceted glioblastoma therapy. Frontiers in Cellular Neuroscience, 11, 318. https://doi.org/10.3389/fncel.2017.00318CrossRef

293.

Hombach-Klonisch, S., Mehrpour, M., Shojaei, S., Harlos, C., Pitz, M., Hamai, A., & Ghavami, S. (2018). Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response. Pharmacology & Therapeutics, 184, 13–41. https://doi.org/10.1016/j.pharmthera.2017.10.017CrossRef

294.

Wu, X., Xiao, S., Zhang, M., Yang, L., Zhong, J., Li, B., & Zhang, N. (2021). A novel protein encoded by circular SMO RNA is essential for Hedgehog signaling activation and glioblastoma tumorigenicity. Genome Biology, 22(1), 33. https://doi.org/10.1186/s13059-020-02250-6CrossRef

295.

Filbin, M. G., Dabral, S. K., Pazyra-Murphy, M. F., Ramkissoon, S., Kung, A. L., Pak, E., & Segal, R. A. (2013). Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: New therapeutic opportunities. Nature Medicine, 19(11), 1518–1523. https://doi.org/10.1038/nm.3328CrossRef

296.

Vik-Mo, E. O., Nyakas, M., Mikkelsen, B. V., Moe, M. C., Due-Tønnesen, P., Suso, E. M., & Langmoen, I. A. (2013). Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunology, Immunotherapy, 62(9), 1499–1509. https://doi.org/10.1007/s00262-013-1453-3CrossRef

297.

Phuphanich, S., Wheeler, C. J., Rudnick, J. D., Mazer, M., Wang, H., Nuño, M. A., & Yu, J. S. (2013). Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunology, Immunotherapy, 62(1), 125–135. https://doi.org/10.1007/s00262-012-1319-0CrossRef

298.

De Vleeschouwer, S. (2020). Vaccines against glioblastoma: reflections on the ICT-107 phase IIb trial. Transl Cancer Res, 9(8), 4473–4475. https://doi.org/10.21037/tcr-2020-004CrossRef

299.

Garros-Regulez, L., Garcia, I., Carrasco-Garcia, E., Lantero, A., Aldaz, P., Moreno-Cugnon, L., & Matheu, A. (2016). Targeting SOX2 as a therapeutic strategy in glioblastoma. Frontiers in Oncology, 6, 222. https://doi.org/10.3389/fonc.2016.00222CrossRef

300.

Ciechomska, I. A., Gielniewski, B., Wojtas, B., Kaminska, B., & Mieczkowski, J. (2020). EGFR/FOXO3a/BIM signaling pathway determines chemosensitivity of BMP4-differentiated glioma stem cells to temozolomide. Experimental & Molecular Medicine, 52(8), 1326–1340. https://doi.org/10.1038/s12276-020-0479-9CrossRef

301.

Cardoso, A. M., Morais, C. M., Pena, F., Marante, T., Cunha, P. P., Jurado, A. S., & Pedroso de Lima, M. C. (2021). Differentiation of glioblastoma stem cells promoted by miR-128 or miR-302a overexpression enhances senescence-associated cytotoxicity of axitinib. Human Molecular Genetics, 30(3–4), 160–171. https://doi.org/10.1093/hmg/ddab011CrossRef

302.

Bovenberg, M. S., Degeling, M. H., & Tannous, B. A. (2013). Advances in stem cell therapy against gliomas. Trends in Molecular Medicine, 19(5), 281–291. https://doi.org/10.1016/j.molmed.2013.03.001CrossRef

303.

Malumbres, M., & Barbacid, M. (2009). Cell cycle, CDKs and cancer: A changing paradigm. Nature Reviews Cancer, 9(3), 153–166. https://doi.org/10.1038/nrc2602CrossRef

304.

Riess, C., Irmscher, N., Salewski, I., Strüder, D., Classen, C. F., Große-Thie, C., & Maletzki, C. (2021). Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma-backbone or add-on in immune-oncology? Cancer and Metastasis Reviews, 40(1), 153–171. https://doi.org/10.1007/s10555-020-09940-4CrossRef

305.

Li, H., Jiang, X., Yu, Y., Huang, W., Xing, H., Agar, N. Y., & Johnson, M. D. (2015). KAP regulates ROCK2 and Cdk2 in an RNA-activated glioblastoma invasion pathway. Oncogene, 34(11), 1432–1441. https://doi.org/10.1038/onc.2014.49CrossRef

306.

Wang, J., Yang, T., Xu, G., Liu, H., Ren, C., Xie, W., & Wang, M. (2016). Cyclin-dependent kinase 2 promotes tumor proliferation and induces radio resistance in glioblastoma. Transl Oncol, 9(6), 548–556. https://doi.org/10.1016/j.tranon.2016.08.007CrossRef

307.

Bellail, A. C., Olson, J. J., & Hao, C. (2014). SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression. Nature Communications, 5, 4234. https://doi.org/10.1038/ncomms5234CrossRef

308.

Hayashi, T., Adachi, K., Ohba, S., & Hirose, Y. (2013). The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells. Journal of Neuro-oncology, 115(2), 169–178. https://doi.org/10.1007/s11060-013-1220-5CrossRef

309.

Lubanska, D., & Porter, L. (2017). Revisiting CDK inhibitors for treatment of glioblastoma multiforme. Drugs R D, 17(2), 255–263. https://doi.org/10.1007/s40268-017-0180-1CrossRef

310.

Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., & Shapiro, G. I. (2016). Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discovery, 6(7), 740–753. https://doi.org/10.1158/2159-8290.CD-16-0095CrossRef

311.

Miller, T. W., Traphagen, N. A., Li, J., Lewis, L. D., Lopes, B., Asthagiri, A., & Fadul, C. E. (2019). Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma. Journal of Neuro-oncology, 144(3), 563–572. https://doi.org/10.1007/s11060-019-03258-0CrossRef

312.

Das, A., Henderson, F. C., Alshareef, M., Porto, G. B. F., Kanginakudru, I., Infinger, L. K., & Cachia, D. (2021). MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells. Clinical and Translational Oncology, 23(3), 612–619. https://doi.org/10.1007/s12094-020-02456-xCrossRef

313.

Quail, D. F., & Joyce, J. A. (2017). The microenvironmental landscape of brain tumors. Cancer Cell, 31(3), 326–341. https://doi.org/10.1016/j.ccell.2017.02.009CrossRef

314.

Katzenelenbogen, Y., Sheban, F., Yalin, A., Yofe, I., Svetlichnyy, D., Jaitin, D. A., & Amit, I. (2020). Coupled scRNA-Seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in cancer. Cell, 182(4), 872-885.e819. https://doi.org/10.1016/j.cell.2020.06.032CrossRef

315.

Galstyan, A., Markman, J. L., Shatalova, E. S., Chiechi, A., Korman, A. J., Patil, R., & Ljubimova, J. Y. (2019). Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy. Nature Communications, 10(1), 3850. https://doi.org/10.1038/s41467-019-11719-3CrossRef

316.

Zhao, M., van Straten, D., Broekman, M. L. D., Préat, V., & Schiffelers, R. M. (2020). Nanocarrier-based drug combination therapy for glioblastoma. Theranostics, 10(3), 1355–1372. https://doi.org/10.7150/thno.38147CrossRef

317.

Kamath, A. A., Friedman, D. D., Akbari, S. H. A., Kim, A. H., Tao, Y., Luo, J., & Leuthardt, E. C. (2019). Glioblastoma treated with magnetic resonance imaging-guided laser interstitial thermal therapy: Safety, efficacy, and outcomes. Neurosurgery, 84(4), 836–843. https://doi.org/10.1093/neuros/nyy375CrossRef

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The multifaceted mechanisms of malignant glioblastoma progression and clinical implications

Abstract

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2022

Oncogenic functions of the FOXC2 transcription factor: a hallmarks of cancer perspective

The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options

Increasing cancer permeability by photodynamic priming: from microenvironment to mechanotransduction signaling

The role of inner nuclear membrane proteins in tumourigenesis and as potential targets for cancer therapy

p73 isoforms meet evolution of metastasis

Physicochemical aspects of the tumour microenvironment as drivers of vasculogenic mimicry

Keynote webinar | Spotlight on antibody–drug conjugates in cancer